A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Clinical Trial ID NCT00503984

Rank	Title	Journal	Year	PubWeight™‹?›
1	DNA methylation and cancer diagnosis.	Int J Mol Sci	2013	1.18
2	Novel targeted therapeutics for metastatic castration-resistant prostate cancer.	Cancer Lett	2009	1.04
3	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.	Prostate Cancer Prostatic Dis	2011	0.93
4	Epigenetics in prostate cancer.	Prostate Cancer	2011	0.92
5	Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.	Hum Mutat	2013	0.92
6	Emerging molecularly targeted therapies in castration refractory prostate cancer.	Prostate Cancer	2013	0.83
7	Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.	Clin Genitourin Cancer	2014	0.79
8	Future directions in castrate-resistant prostate cancer therapy.	Clin Genitourin Cancer	2010	0.79
9	Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.	Transl Res	2014	0.78
10	Epigenetic modulators as therapeutic targets in prostate cancer.	Clin Epigenetics	2016	0.76